NeuroMetrix to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference

NeuroMetrix to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--Nov. 29, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity 6^th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference at the St. Regis Hotel, San Francisco, CA on December 6, 2011. Dr. Gozani intends to provide an update on the Company’s business activities and on its new product NC-stat® DPNCheck^TM for testing of systemic neuropathies such as diabetic peripheral neuropathy (DPN).

NeuroMetrix's presentation is scheduled for Tuesday, December 6, 2011 at 2:40 pm (Pacific Daylight Time), 5:40 pm (Eastern Daylight Time). A live audio webcast will be available on the investor relations section of the corporate website - www.neurometrix.com. This webcast will be archived after the live event.

About NeuroMetrix

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit http://www.neurometrix.com.

Source: NeuroMetrix, Inc.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com